Evidence map›Paper›PMID 36943122›Full record

ReviewMedecine sciences : M/S2023

[Cystinosis: From the gene identification to the first gene therapy clinical trial].

Stéphanie Cherqui

Open access · bronzeAbstract readReviewEnglish Abstract
In one paragraph

Review in Medecine sciences : M/S, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Frontiers in immunology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Stéphanie CherquiDepartment of Pediatrics, Division of Genetics, University of California, San Diego, La Jolla, California, États-Unis.
University of California San Diego · US

Funding

Lentiviral-transduced hematopoictic stem cell transplantation for cystinosisR01DK090058 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHERQUI, STEPHANIE · 2011 to 2019
$2.7M
Hematopoietic Stem Cell Gene Therapy for Friedreich's ataxiaR01NS108965 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHERQUI, STEPHANIE · 2018 to 2022
$1.7M
NIDDK NIH HHS R01 DK090058NINDS NIH HHS R01 NS108965
6 · The paper itself

Abstract

Cystinosis is an autosomal recessive metabolic disease characterized by lysosomal accumulation of cystine in all the cells of the body. Infantile cystinosis begins in infancy by a renal Fanconi syndrome and eventually leads to multi-organ failure, including the kidney, eye, thyroid, muscle, and pancreas, eventually causing premature death in early adulthood. The current treatment is the drug cysteamine that only delays the progression of the disease. We identified the gene involved, CTNS, and showed that the encoded protein, cystinosin, is a proton-driven cystine transporter. We generated a mouse model of cystinosis, the Ctns

Indexed as

Amino Acid Transport Systems, NeutralCystinosisAdultAnimalsClinical Trials as TopicCysteamineCystineGenetic TherapyHumansKidneyMiceAmino Acid Transport Systems, NeutralCysteamineCystine

Identifiers

PMID36943122
PMCPMC10629270
OpenAlexW4328048487

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.